Arrivent Biopharma Inc
AVBP18.780USD
+0.120+0.64%
收盤 08/04, 16:00（美東）報價延遲15分鐘
639.29M總市值
虧損本益比TTM
關於 Arrivent Biopharma Inc 公司
ArriVent Biopharma, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於識別、開發和商業化差異化藥物，以滿足癌症患者未滿足的醫療需求。其主要開發候選藥物 Furmonertinib 正在推進一系列新型療法，例如抗體藥物偶聯物，通過批准和商業化用於癌症患者，最初重點是實體瘤。Furmonertinib 是一種口服、高度腦滲透性、活性突變選擇性 EGFR 抑制劑，針對經典（外顯子 19 缺失和 L858R）和罕見 EGFR 突變，包括外顯子 20 插入突變，以及 HER2 外顯子 20 插入突變。Furmonertinib 是一種研究性、新型、EGFR 突變選擇性酪氨酸激酶抑制劑，正在開發用於治療一組 EGFR 突變的 NSCLC 患者。它還專注於 ARR-002 計劃的開發和商業化。
公司簡介
公司代碼AVBP
公司名稱Arrivent Biopharma Inc
上市日期Jan 26, 2024
CEODr. Zhengbin (Bing) Yao, Ph.D.
員工數量52
證券類型Ordinary Share
年結日Jan 26
公司地址18 Campus Blvd.
城市NEWTOWN SQUARE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編19073-3269
電話12407806356
網址https://arrivent.com/
公司代碼AVBP
上市日期Jan 26, 2024
CEODr. Zhengbin (Bing) Yao, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Mr. Chris W. Nolet
Mr. Chris W. Nolet
Independent Director
Independent Director
--
--
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Zhengbin (Bing) Yao, Ph.D.
Dr. Zhengbin (Bing) Yao, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Lead Independent Director
Lead Independent Director
--
--
Dr. Merdad V. Parsey, M.D., Ph.D.
Dr. Merdad V. Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Mr. Chris W. Nolet
Mr. Chris W. Nolet
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
HHLR Advisors, Ltd.
12.09%
OrbiMed Advisors, LLC
8.16%
Suvretta Capital Management, LLC
6.30%
Fidelity Management & Research Company LLC
5.60%
INFINITUM ASSET MANAGEMENT, LLC
5.57%
Other
62.28%
持股股東
持股股東
佔比
HHLR Advisors, Ltd.
12.09%
OrbiMed Advisors, LLC
8.16%
Suvretta Capital Management, LLC
6.30%
Fidelity Management & Research Company LLC
5.60%
INFINITUM ASSET MANAGEMENT, LLC
5.57%
Other
62.28%
股東類型
持股股東
佔比
Investment Advisor
24.89%
Investment Advisor/Hedge Fund
17.77%
Venture Capital
13.65%
Hedge Fund
12.94%
Private Equity
8.16%
Corporation
5.52%
Individual Investor
3.50%
Research Firm
0.61%
Bank and Trust
0.47%
Other
12.49%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
170
32.49M
87.70%
-3.54M
2025Q1
168
36.33M
107.08%
+4.56M
2024Q4
146
35.70M
104.98%
+7.05M
2024Q3
118
33.13M
98.31%
+8.97M
2024Q2
99
30.18M
90.13%
+6.97M
2024Q1
80
30.36M
90.72%
+24.09M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
HHLR Advisors, Ltd.
4.48M
12.09%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
3.03M
8.16%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
2.34M
6.3%
+91.50K
+4.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.08M
5.6%
-22.38K
-1.07%
Mar 31, 2025
INFINITUM ASSET MANAGEMENT, LLC
2.07M
5.57%
--
--
May 01, 2025
Octagon Capital Advisors LP
2.06M
5.55%
--
--
Mar 31, 2025
LAV Fund VI LP
2.05M
5.52%
+2.05M
--
Jan 26, 2024
BlackRock Institutional Trust Company, N.A.
1.95M
5.27%
-8.68K
-0.44%
Mar 31, 2025
Novo Holdings A/S
1.87M
5.05%
+122.14K
+6.98%
Mar 31, 2025
Sofinnova Investments, Inc
1.70M
4.57%
--
--
Apr 21, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
iShares Micro-Cap ETF
0.11%
SPDR S&P Biotech ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.83%
iShares Micro-Cap ETF
佔比0.11%
SPDR S&P Biotech ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.08%
Invesco Nasdaq Biotechnology ETF
佔比0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.05%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.05%
Vanguard US Momentum Factor ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
iShares Russell 2000 Growth ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
